Coronavirus Disease-19-associated Mucormycosis: A Single-center Observational Study of 69 Patients.
| Title: | Coronavirus Disease-19-associated Mucormycosis: A Single-center Observational Study of 69 Patients. |
|---|---|
| Authors: | Yadav DS; Assistant Professor, Department of Medicine, Lokmanya Tilak Municipal General Hospital and Lokmanya Tilak Municipal Medical College, Mumbai, Maharashtra, India.; Chavan SA; Professor, Department of Medicine, Lokmanya Tilak Municipal General Hospital and Lokmanya Tilak Municipal Medical College, Mumbai, Maharashtra, India.; Karnik ND; Professor and Head of Department, Department of Medicine, Lokmanya Tilak Municipal General Hospital and Lokmanya Tilak Municipal Medical College, Mumbai, Maharashtra, India.; Kumar CA; Additional Professor, Department of Microbiology, Lokmanya Tilak Municipal General Hospital and Lokmanya Tilak Municipal Medical College, Mumbai, Maharashtra, India, Corresponding Author.; Padhiyar RN; Associate Professor, Department of Medicine, Lokmanya Tilak Municipal General Hospital and Lokmanya Tilak Municipal Medical College, Mumbai, Maharashtra, India.; D'Souza D; Associate Professor, Department of Microbiology, Lokmanya Tilak Municipal General Hospital and Lokmanya Tilak Municipal Medical College, Mumbai, Maharashtra, India. |
| Source: | The Journal of the Association of Physicians of India [J Assoc Physicians India] 2024 Oct; Vol. 72 (10), pp. 24-31. |
| Publication Type: | Journal Article; Observational Study |
| Language: | English |
| Journal Info: | Publisher: Association of Physicians of India Country of Publication: India NLM ID: 7505585 Publication Model: Print Cited Medium: Print ISSN: 0004-5772 (Print) Linking ISSN: 00045772 NLM ISO Abbreviation: J Assoc Physicians India Subsets: MEDLINE |
| Imprint Name(s): | Publication: Bombay : Association of Physicians of India; Original Publication: Bombay [1953?]- |
| MeSH Terms: | Mucormycosis*/complications ; Mucormycosis*/epidemiology ; Mucormycosis*/diagnosis ; COVID-19*/complications ; COVID-19*/mortality; India/epidemiology ; Antifungal Agents/therapeutic use ; Humans ; Male ; Middle Aged ; Female ; Retrospective Studies ; Adult ; Risk Factors ; Aged ; SARS-CoV-2 |
| Abstract: | Background and Objectives: We studied the clinical presentation, risk factors, complications, and in-hospital outcomes of patients with coronavirus disease 2019 (COVID-19)-associated mucormycosis (CAM).; Materials and Methods: A retrospective study was done on 69 COVID-19 patients with microbiologically proven mucormycosis admitted over a period of seven months from March 2021 to September 2021.; Results: All 69 mucormycosis patients (46 males, 23 females) had reverse transcriptase-polymerase chain reaction (RT-PCR)-confirmed COVID-19 infection. Their mean age was 52.8 years, with mucormycosis developing in 51 patients (73.9%) within 30 days of COVID-19 infection; 7 (10.1%) were positive on admission. Rhino-orbital-cerebral mucormycosis (ROCM) was the most common (40.3%), followed by rhino-orbital (37.3%) and sinonasal (22.4%). Diabetes mellitus was present in 98.6% of patients. Common symptoms of mucormycosis were facial pain, headache, facial swelling, and vision loss. During COVID-19, 88.4 and 52.5% received immunosuppressive treatment and zinc sulfate, respectively; 34.7% needed intensive care unit (ICU) admission. The mortality rate was 26.1%. On multivariate logistic regression analysis, the presence of chronic kidney disease, leukocytosis, ophthalmoplegia, oral/palate ulceration, current need for invasive ventilation, and past duration of oxygen therapy and zinc supplementation were significantly associated with mortality. Patients with current COVID-19 infection had severe disease with increased need for intensive care (57.1 vs 14.5%) and higher mortality (57.1 vs 22.6%) compared to mucormycosis patients with previous COVID-19 infection.; Interpretation and Conclusion: Rhino-orbital-cerebral, rhino-orbital, and sinonasal were the most common presentations in cases of mucormycosis, with a mortality rate of 26.1%. COVID-19 coinfection predisposes patients with mucormycosis to severe disease with higher mortality.; (© Journal of the Association of Physicians of India 2024.) |
| Substance Nomenclature: | 0 (Antifungal Agents) |
| Entry Date(s): | Date Created: 20241011 Date Completed: 20241011 Latest Revision: 20250122 |
| Update Code: | 20260130 |
| DOI: | 10.59556/japi.72.0684 |
| PMID: | 39390855 |
| Database: | MEDLINE |
Journal Article; Observational Study